ZAP-X Gyroscopic Radiosurgery Platform to Debut in Taiwan at Kaohsiung Show Chwan Memorial Hospital
ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that the first vault-free ZAP-X® Gyroscopic Radiosurgery® platform in Taiwan will be installed at Kaohsiung Show Chwan Memorial Hospital (KSCH). This marks a significant milestone in the region's adoption of cutting-edge stereotactic radiosurgery (SRS) technology. Installation is set to begin in Q4 2025, with patient treatments expected to commence in Q1 2026.
This press release features multimedia. View the full release here:
Architectural renderings of the ZAP-X Gyroscopic Radiosurgery platform at Kaohsiung Show Chwan Memorial Hospital, Taiwan. Leveraging a first-in-kind vault-free design, KSCH looks to showcase ZAP-X as a signature service for the hospital's new neuro-oncology program.
KSCH, a newly opened medical facility, is the latest addition to the Show Chwan Healthcare System, one of Taiwan's leading medical networks. With the introduction of ZAP-X, KSCH aims to further elevate its existing Neuro-Oncology practice, offering advanced, non-invasive treatment options for patients with primary and metastatic brain tumors, as well as other neurological disorders.
Stereotactic radiosurgery (SRS) is a completely non-invasive and painless procedure that has emerged as a game-changer in the treatment of brain tumors and other disorders of the brain, head, and neck. Unlike conventional open surgery, SRS requires no incision, and treatments typically require just a single brief outpatient visit. It is not uncommon for patients to return to normal activities the same day as treatment.
'SRS is revolutionizing the way we treat brain tumors and neurological conditions,' said Dr. Min-Ho Huang, President of Show Chwan Healthcare System. 'With the addition of ZAP-X at KSCH, we are reinforcing our commitment to providing world-class, non-invasive treatment solutions to patients in Taiwan and beyond.'
The adoption of ZAP-X at KSCH represents a significant step forward in Taiwan's neuro-oncology landscape. The system eliminates the need for costly shielded radiation treatment rooms, making advanced radiosurgery more accessible. Additionally, unlike historical systems that rely on Cobalt-60 radioactive sources, ZAP-X utilizes a modern linear accelerator for radiation generation, reducing the logistical and financial burdens of handling and regularly replacing radioactive isotopes.
The ZAP-X system is distinguished by its unique gyroscopic maneuverability, enabling the delivery of radiosurgical beams from thousands of potential angles to precisely target tumors while minimizing radiation exposure to critical structures such as the brain stem, eyes, and optic nerves. This innovative approach also enhances patient safety and preserves cognitive function by reducing radiation exposure to healthy brain tissue.
Show Chwan Healthcare System has historically treated SRS patients with Cobalt-60-based delivery technology. The addition of ZAP-X provides a next-generation alternative that aims to enhance treatment versatility and precision.
For details on ZAP-X and its technology, visit www.zapsurgical.com.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Senior Vice President, Marketing
+1 650 492 7797, ext. 101
KEYWORD: TAIWAN ASIA PACIFIC
SOURCE: ZAP Surgical Systems, Inc.
Copyright Business Wire 2025.
PUB: 04/01/2025 07:15 AM/DISC: 04/01/2025 07:15 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
14 hours ago
- Business Upturn
Support from the Ministry of the French Armed Forces for the development of Dassault Aviation's VORTEX spaceplane demonstrator
Support from the Ministry of the French Armed Forces for the development of Dassault Aviation's VORTEX spaceplane demonstrator (Saint-Cloud, June 20, 2025) – At the Paris Air Show today, Sébastien Lecornu, Minister of the French Armed Forces, and Eric Trappier, Chairman and CEO of Dassault Aviation, announced the signing of an agreement to support the development of a spaceplane demonstrator. This demonstrator represents the first step in an incremental and intrinsically dual roadmap for the development of a family of spaceplanes called VORTEX (Véhicule Orbital Réutilisable de Transport et d'Exploration). In line with its key role in national aeronautical sovereignty, Dassault Aviation is building this roadmap to contribute to the development of key strategic capabilities and meet the new challenges of the space economy. It addresses multiple applications, including transport to and from orbit, and civil and military missions for an autonomous orbital platform. Drawing on Dassault Aviation's solid and recognised industrial expertise as an architect and integrator of complex airborne systems, reinforced by that acquired in the space sector on such emblematic projects as Hermès, the X-38 and the IXV, this demonstrator aims to validate the critical performances associated with the configuration of a spaceplane, in particular control of hypersonic flight, advanced thermal protection technologies and flight control. These demonstration objectives are an essential step in reducing technological uncertainties and preparing for future decisions on operational space capabilities, both military and civilian. By adopting an agile innovation approach aimed at accelerating the maturation of critical technologies and disruptive concepts, Dassault Aviation is embracing the spirit of NewSpace, optimizing industrial processes and seeking the optimum balance between technical performance, development time, risk mitigation and cost efficiency. ' Like Dassault Aviation's civil and military aircraft, the VORTEX spaceplane is designed to be highly versatile. It will contribute to transforming the uses of the space sector and opening up new fields of application . At the crossroads of aviation and space technologies, the VORTEX will undoubtedly pave the way for a new generation of space aeronautics, consolidating France's strategic position as a leading space power. Dassault Aviation is proud to take on this historic challenge and thanks the French Ministry of Armed Forces for its confidence. ' said Eric Trappier. * * ABOUT DASSAULT AVIATION: With over 10,000 military and civil aircraft (including 2,700 Falcons) delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized worldwide in the design, production, sale and support of all types of aircraft, ranging from the Rafale fighter, to the high-end Falcon family of business jets, military drones and space systems. In 2024, Dassault Aviation reported revenues of €6.2 billion. The company has 14,600 employees. PRESS CONTACTS: Corporate Communications Stéphane Fort: +33 (0)1 47 11 86 90 – [email protected] Mathieu Durand: +33 (0)1 47 11 85 88 – [email protected] Defense Communication Nathalie Bakhos: +33 (0)1 47 11 84 12 – [email protected] HD photos: HD videos: Attachment PR_Dassault Aviation Vortex GB Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
14 hours ago
- Yahoo
Lumen (LUMN) Subsidiary to Raise $1B for AI-Focused Debt Refinancing
Lumen Technologies, Inc. (NYSE:LUMN) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, the company announced its wholly owned subsidiary Level 3 Financing plans to raise $1 billion in the market to refinance debt. An aerial view of a communications satellite in orbit, beaming its signal down to Earth. Level 3 will offer a $1 billion aggregate principal of First Lien Notes due in 2033. The unit will leverage net proceeds from the offering to redeem all $924.522 million in aggregate principal amount of senior secured notes due in 2030. The refinancing move extends the maturity date of Level 3 financing debt from 2030 to 2033. Lumen Technologies, Inc. (NYSE:LUMN) is a global communications and IT services company that offers solutions that help businesses connect people's data and applications securely. Its solutions also help companies realize artificial intelligence potential through its metro connectivity edge cloud and managed service capabilities. While we acknowledge the potential of LUMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None. Sign in to access your portfolio
